WO 2005/087250 PCT/US2004/004142

## What is claimed is:

 A method of treating a condition associated with ocular neovascularization in a subject comprising administration of a peptide comprising the amino acid sequence of SEQ ID NO: 1.

- A method of treating a condition associated with ocular neovascularization in a subject comprising administration of a peptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.
- 3. The method of claims 1 or 2, wherein said ocular neovascularization is choroidal neovascularization.
  - 4. The method of claim 3, wherein said condition is age-related macular degeneration (AMD) or high myopia.
  - 5. The method of claims 1 or 2, wherein said ocular neovascularization is retinal neovascularization.
- 15 6. The method of claim 5, wherein said condition is diabetic retinopathy, retinopathy of prematurity, or central vein occlusion.
  - 7. The method of claims 1 or 2, wherein said ocular neovascularization is iris neovascularization.
  - 8. The method of claim 7, wherein said condition is neovascular glaucoma.
- 20 9. The method of claims 1 or 2, wherein said peptide further comprises a modification.
  - 10. The method of claim 9, wherein said modification is selected from the group consisting of addition of an antibody Fc and pegylation.

WO 2005/087250 PCT/US2004/004142

11. The method of claims 1 or 2, wherein said peptide comprises one or more Deform amino acids.

- 12. The method of claim 1 or 2, wherein said peptide contains an N-terminal amide.
- 5 13. A method of treating cancer in a subject comprising administration of a peptide comprising the amino acid sequence of SEQ ID NO: 1.
  - 14. A method of treating cancer in a subject comprising administration of a peptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.
- 10 15. The method of claims 13 or 14, wherein said cancer is breast cancer.
  - 16. The method of claims 13 or 14, wherein said peptide further comprises a modification.
  - 17. The method of claim 16, wherein said modification is selected from the group consisting of addition of an antibody Fc and pegylation.
- 15 18. The method of claims 13 or 14, wherein said peptide comprises one or moreD form amino acids.
  - 19. The method of claim 13 or 14, wherein said peptide contains an N-terminal amide.
- 20. A pharmaceutical composition comprising a peptide comprising the amino20 acid sequence of SEQ ID NO: 1.
  - 21. A pharmaceutical composition comprising a peptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.

WO 2005/087250 PCT/US2004/004142

22. The pharmaceutical composition of claims 20 or 21, wherein said peptide further comprises a modification.

- 23. The pharmaceutical composition of claim 22, wherein said modification is selected from the group consisting of addition of an Fc antibody and pegylation.
- 5 24. The pharmaceutical composition of claims 20 or 21, wherein said peptide comprises one or more D form amino acids.
  - 25. The pharmaceutical composition of claims 20 or 21, wherein said peptide contains an N-terminal amide.
  - 26. A kit for the treatment of a condition associated with ocular neovascularization in a subject comprising (a) a composition comprising a peptide comprising the amino acid sequence of SEQ ID NO: 1 and (b) instructions for administration of said composition.


10

15

20

- 27. A kit for the treatment of a condition associated with ocular neovascularization in a subject comprising (a) a composition comprising a peptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5 and (b) instructions for administration of said composition.
- 28. A kit for the treatment of cancer in a subject comprising (a) a composition comprising a peptide comprising the amino acid sequence of SEQ ID NO: 1 and (b) instructions for administration of said composition.
- 29. A kit for the treatment of cancer in a subject comprising (a) a composition comprising a peptide with an amino acid sequence selected from the group





consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5 and (b) instructions for administration of said composition.